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Abstract: TRPC6 plays a critical role in proteinuric kidney diseases, and TRPC3 is involved in tubulointerstitial 
damage and renal fibrosis in obstructed kidneys. Podocyte loss is a characteristic event in diabetic nephropathy 
(DN). The aim of this study was to examine whether deletion of the closely related diacylglycerol (DAG)-responsive 
TRPCs in mice (TRPC3/6/7-/-) affects diabetes-induced renal dysfunction and podocyte loss. We compared urine 
volume, kidney hypertrophy, glomerular enlargement, albuminuria and podocyte loss between wild type (WT) and 
TRPC3/6/7-/- diabetic mice. Finally, we examined whether the TGFβ1 signaling pathway is changed in diabetic WT 
and TRPC3/6/7-/- mice. TRPC6 protein in the renal cortex was increased in WT diabetic mice. High glucose (HG) 
treatment increased TRPC6 expression in human podocytes. TRPC3 protein, however, was not altered in either 
diabetic mice or HG-treated human podocytes. Although diabetic WT and TRPC3/6/7-/- mice had similar levels of 
hyperglycemia, the TRPC3/6/7-/- diabetic mice showed less polyuria, kidney hypertrophy, glomerular enlargement, 
albuminuria, and had lost less podocytes compared with WT diabetic mice. In addition, we observed decreased 
expression of anti-apoptotic Bcl2 and increased expression of pro-apoptotic cleaved caspase 3 in WT diabetic mice, 
but such changes were not significant in TRPC3/6/7-/- diabetic mice. Western blot and immunohistochemistry re-
vealed that TGFβ1, p-Smad2/3, and fibronectin were upregulated in WT diabetic mice; however, expression of these 
signaling molecules was not changed in TRPC3/6/7-/- diabetic mice. In conclusion, deletion of DAG-responsive 
TRPCs attenuates diabetic renal injury via inhibiting the upregulation of TGFβ1 signaling in diabetic kidneys. 
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Introduction
Diabetic nephropathy (DN) is a major microvas-
cular complication of diabetes mellitus and the 
leading cause worldwide of end-stage renal dis-
ease [1]. The characteristic pathological chan- 
ges of DN include severe albuminuria, renal 
hyperfiltration, glomerular basement mem-
brane thickening, and glomerulosclerosis [2]. 
Podocytes are crucial components of the glo-
merular capillary filter. Damage to the glomeru-
lar capillary filter, particularly at the level of the 
podocyte and the slit diaphragm, is of crucial 
importance in the pathogenesis of DN, which 
eventually leads from microalbuminuria to 
overt proteinuria with renal function decline.
The canonical transient receptor potential (TR- 
PC) channels are a family of Ca2+-permeable 
non-selective cation channels with seven mem-
bers, i.e., TRPC1 to TRPC7. This family can be 
further divided into two major subfamilies ba- 
sed on their functional similarities and se- 
quence alignment: TRPC1/4/5 and TRPC3/6/7 
(TRPC2 is a pseudogene in humans) [3]. In addi-
tion to sequence similarity, TRPC3/6/7 share 
the property of being activated by diacylglycer-
ols (DAG). TRPC6 has been identified as a slit 
diaphragm associated protein in podocytes [4, 
5]. Gain of function mutants of TRPC6 were 
identified in patients with proteinuria due to 
inherited forms of focal segmental glomerulo-
sclerosis (FSGS) in their kidney glomeruli [4, 5]. 
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Transient in vivo gene delivery of TRPC6 into 
mice leads to the expression of TRPC6 protein 
at the slit diaphragm that causes proteinuria 
[6]. Moreover, TRPC6-deficient (TRPC6-/-) mice 
show significantly less angiotensin II-induced 
proteinuria compared with wild type mice [7], 
indicating that TRPC6 activation is also involv- 
ed in the pathology of acquired proteinuric kid-
ney disease, such as DN. In vitro studies have 
shown that high glucose levels induce podo-
cyte apoptosis via upregulation of TRPC6 [8, 9]. 
Besides TRPC6, a recent study demonstrated 
that TRPC3 is involved in renal injury, by show-
ing that TRPC3 knockout in mice ameliorates 
tubulointerstitial damage and renal fibrosis in 
obstructed kidneys [10]. 
It has been established that transforming grow- 
th factor β1 (TGFβ1) is involved in the patho-
genesis of DN [11]. Gain-of-function mutation 
of TRPC6 results in extracellular signal-regulat-
ed kinases 1/2 (ERK1/2) activation in cultured 
podocytes [12], followed by activation of the 
TGFβ-Smad2/3 signaling pathway, downregula-
tion of Bcl2, and upregulation of cleaved cas-
pase 3, which leads to a reduction in the podo-
cyte number per glomerulus and the develop-
ment of albuminuria [13]. Conversely, TGFβ1 
induces podocyte injury through TRPC6 phos-
phorylation [14], suggesting that there may 
be a positive feedback between TGFβ1 and 
TRPC6.
Given that TRPC3 and TRPC6 are deleterious to 
kidney disease and that they are of the same 
DAG-activated channel subfamily, we hypothe-
sized that deletion of DAG-responsive class of 
TRPC genes (TRPC3/6/7) would attenuate dia-
betic renal injury. In this study, type 1 diabetes 
mellitus was induced in wild type (WT) and 
TRPC3/6/7-deleted (TRPC3/6/7-/-) mice on a 
mixed C57BL/6J-129SvEv background using 
streptozotocin (STZ). Compared with their dia-
betic WT counterparts, diabetic TRPC3/6/7-/- 
mice displayed less polyuria, kidney hypertro-
phy, glomerular enlargement, albuminuria, and 
had reduced the loss of podocytes. The protec-
tive effect of TRPC3/6/7 deletion may be attrib-
uted to the inhibition of up-regulated TGFβ1 
signaling in diabetic kidneys.
Materials and methods
Reagents 
The primary antibodies used for western blot or 
immunohistochemistry were as follows: rabbit 
polyclonal anti-TRPC3 antibody (Cat#: ACC-
016, Alomone Labs, Israel); rabbit polyclonal 
anti-TRPC6 antibody (Cat#: ACC-017, Alomone 
Labs, Israel); rabbit polyclonal anti-Bcl2 anti-
body (Cat#: 12789-1-AP, Proteintech, USA); rab-
bit polyclonal anti-Cleaved caspase 3 antibody 
(Cat#: 9661, Cell Signaling Technology, USA); 
rabbit polyclonal anti-WT-1 antibody (Cat#: sc- 
192, Santa Cruz, USA); rabbit polyclonal anti-
TGFβ1 antibody (Cat#: 18978-1-AP, Proteintech, 
USA); rabbit polyclonal anti-p-Smad2/3 anti-
body (Cat#: 8828, Cell Signaling Technology, 
USA); mouse monoclonal anti-Fibronectin anti-
body (Cat#: F7387, Sigma-aldrich, USA); mouse 
monoclonal anti-β-actin antibody (Cat#: TA-09, 
Zhongshan jinqiao, China). STZ, D-glucose and 
mannitol were purchased from Sigma (Louis, 
MO).
Experimental animals and protocol
TRPC3/6/7-/- mice on a mixed C57BL/6J-129- 
SvEv background and WT C57BL/6J/129SvEv 
mice were reconstituted from cryopreserved 
embryos. TRPC3/6/7 triple knockout (KO) par-
ents were generated by crossing TRPC3 KO 
[15], TRPC6 KO [16], and TRPC7 KO [17] mice 
to the desired homozygosity at the Compara- 
tive Medicine Branch (CMB) of the National 
Institute of Environmental Health Sciences, 
North Carolina. The animals were housed at 
22°C, 50% humidity with a 12 h-light/12 h-dark 
cycle with unlimited access to water and food.
Male TRPC3/6/7-/- and WT mice at 6 weeks of 
age were injected with three consecutive intra-
peritoneal injections of STZ 100 mg/kg body 
weight (Sigma, St. Louis, Mo, USA) or vehicle 
(Veh), as described by the Animal Models of 
Diabetic Complications Consortium. Unrestrict- 
ed food and water were provided throughout 
the duration of the experiment. Diabetes was 
defined as a non-fasting blood glucose level 
above 17 mmol/l. All mice were sacrificed 12 
weeks after the first injection for tissue collec-
tion. This study was carried out in strict accor-
dance with the recommendations in the Guide 
for Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was 
approved by the Committee on the Ethics of 
Animal Experiments of the Tongji Medical 
College, Huazhong University of Science and 
Technology. 
Cell culture 
The human podocyte cell line was a gift from 
Dr. Chun Zhang (Union Hospital, Tongji Medical 
college) [18], which was established and cul-
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tured as described previously [19]. In brief, 
cells were cultured in RPMI-1640 medium 
(Hyclone, USA) supplemented with 10% fetal 
bovine serum (Hyclone, USA) at 33°C (‘permis-
sive’ conditions). To induce differentiation, the 
cells were transferred to 37°C (‘non-permis-
sive’ conditions) and kept in culture for 10 days. 
After 16 h of serum starvation, cells were treat-
ed for 6 days with high glucose (HG, 40 mM, 
D-glucose), normal glucose (NG, 5.6 mM), and 
normal glucose with added 34.4 mM mannitol 
(NG+M, 40 mM).
RT-PCR
Total RNA from the WT mouse brain and renal 
cortex and from the TRPC3/6/7-/- mouse brain 
was isolated using the Trizol reagent (Invitrogen, 
USA). First strand cDNA was synthesized using 
SuperScript II Reverse Transcriptase (Invitro- 
gen, USA) and Oligo (dT)12-18 oligonucleotide 
primers in accordance with the manufacturer’s 
instructions. The primer sequences for TRPC1-
TRPC7 are listed in Table 1.
Blood glucose measurement
Body weights and blood glucose levels were 
recorded every 4 weeks. Blood glucose levels 
were measured between 8:30 AM and 10:30 
AM using Accu-chek Performa (Roche, Mann- 
heim, Germany). Approximately 3 μl of blood 
were collected in conscious mice via tail vein 
puncture. 
24 h albuminuria assessment 
24 h albuminuria was assessed as described 
[20]. In brief, 24 h urine collections were ob- 
tained from mice before sacrifice by housing 
them in individual mouse metabolic cages with 
free access to water and rodent mash, and 
adjusted to the same volume using pure water. 
Albumin standards were prepared by serial dilu-
tion of BSA (Sigma, St. Louis, Mo, USA). Samples 
of standards or urine were mixed with 5× SDS-
sample buffer, boiled for 5 min, and analyzed 
by 10% SDS-polyacrylamide gel electrophore-
sis followed by Coomassie blue staining. The 
BSA bands (~65 kDa) were scanned and quan-
tified using NIH ImageJ software. 
Glomerular volume calculation 
Before harvesting kidney tissues, mice were 
anaesthetized and perfused with PBS via left 
ventricle puncture. Kidneys were removed, and 
the kidney capsule was stripped. The kidney 
weight was then recorded. Kidneys were fixed 
in 4% paraformaldehyde for 16-18 h and em- 
bedded in paraffin, cut to 3 μm thickness, and 
stained with periodic acid-Schiff (PAS) reagent. 
Mean glomerular volumes (VG) were calculated 
from mean cross-sectional areas (AG) by Aperio 
ImageScope software (Aperio Technologies 
Inc., Vista, CA, USA) using the equation VG = β/k 
× AG
3/2 where the shape coefficient for sphere β 
= 1.38 and the size distribution coefficient k = 
1.1 [21]. All glomerular profiles from each PAS 
section were used for quantification of glomer-
ular volume, with an average of approximately 
100 glomerular profiles for each animal.
Western blot
Mouse renal cortex or human podocytes were 
lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-
HCl, 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 1 mM EDTA, pH 7.4) containing 
1% protease inhibitor cocktail and 1 mmol/l 
PMSF on ice. Equal amounts of protein lysate 
(50 μg/well) were separated by electrophore- 
sis in 12% or 15% SDS-PAGE gels, transferred 
to polyvinylidene difluoride membranes, and 
blocked for 1 h at room temperature with Tris-
buffered saline with 0.1% Tween 20 (TBST) and 
5% nonfat dry milk. After blocking, membranes 
were incubated with the corresponding primary 
antibodies (anti-TRPC6 1:500; anti-TRPC3 1: 
500; anti-Wilms tumor protein (WT-1) 1:1000; 
Table 1. Primer sequences for TRPC1-TRPC7
Gene Forward Reverse
TRPC1 5’-CTCAAAGTGGTGGCTCACAACAAG-3’ 5’-CATAGAGCTGAGTCAGTCCAATCG-3’
TRPC2 5’-GGCTGTCAACTACAACCAGAAACAG-3’ 5’-AGCTGGCAGAATATATGCCAGTCG-3’
TRPC3 5’-GGACTGTCTGAAGTGACTTCTGTTG-3’ 5’-CTCGAGTGAGACTGTGTGAAGAGG-3’
TRPC4 5’-GTGGAGTGGATGATATTACCGTGG-3’ 5’-TCAGGATGTCCAGAAGCATCCTTC-3’
TRPC5 5’-TCCATGATTGGTGGAACCTGATGG-3’ 5’-AGCATATTCAGCAGCACTACCAGG-3’
TRPC6 5’-CCTACTGATCCTCAGATCATCTCTG-3’ 5’-CTCTGCATCTTCTTGGAAGCCTTG-3’
TRPC7 5’-GACGGAGATGCTCATCATGAAGTG-3’ 5’-CGGTAGTAGGAGTACAGGTTGAAC-3’
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anti-Bcl2 1:1000; anti-Cleaved caspase 3 1: 
500; anti-TGFβ1 1:500; anti-p-Smad2/3 1:500; 
anti-β-actin 1:500) in TBST overnight at 4°C. 
After being washed in TBST, membranes were 
exposed to horseradish peroxidase (HRP)-con- 
jugated goat anti-mouse or goat anti-rabbit 
IgGs secondary antibody (1:20000) and wash- 
ed once again. The immunoreactive bands 
were visualized by chemiluminescence. Quan- 
tification was performed by measuring the 
intensity of the bands with the aid of NIH ImageJ 
software. The expression level of each protein 
was normalized to β-actin on the same blot.
Immunohistochemistry 
Dewaxed tissue sections were boiled with anti-
gen-retrieval solution (0.01 M Citrate Buffer, pH 
6.0) for 15-20 min in a microwave oven. Sec- 
tions were incubated with the corresponding 
primary antibodies (anti-TGFβ1 1:100, anti-
Fibronectin 1:100) overnight at 4°C, followed 
by incubation with the secondary antibody for 1 
h, revealed with DAB (Vector Laboratories), and 
counterstained with hematoxylin. 
Statistical analysis 
Data were expressed as means ± SEM. Graph- 
Pad Prism 5 (GraphPad Software, La Jolla, CA, 
USA) was used for statistical analysis. For mul-
tiple group comparisons, one-way ANOVA with 
Bonferroni’s post hoc test was performed and 
for two group comparisons, unpaired t-test was 
performed. p<0.05 was considered statistically 
significant.
Figure 1. Hyperglycemia (high glucose) increases TRPC6. A, B. RT-PCR showed that TRPC1, TRPC2, TRPC3, TRPC4 
and TRPC6 were expressed in the mouse renal cortex, while TRPC5 and TRPC7 were not detectable. C. Western blot 
analysis demonstrated that the TRPC6 protein level of kidney cortical lysates was significantly increased in diabetic 
mice compared with nondiabetic mice (*p<0.05), while TRPC3 was unaltered. n=5 mice/group. D. Differentiated 
human podocytes were treated with high glucose for 6 days. Western blot analysis showed that high glucose in-
creased TRPC6 protein level obviously (***p<0.0001), while TRPC3 was not affected. The administration of man-
nitol was performed to exclude osmotic effects. NG, normal glucose (5.6 mmol/l); HG, high glucose (40 mmol/l); 
NG+M, normal glucose with added 34.4 mmol/l mannitol. Data are representative of three separate experiments. 
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Results
Hyperglycemia or high glucose increases 
TRPC6 expression
The expression of TRPC mRNAs in the renal 
cortex was examined by RT-PCR (Figure 1B). 
Figure 1A demonstrates the presence of mRNA 
for TRPC1-TRPC7 in the mouse brain (positive 
controls). As shown in Figure 1B, only TRPC1, 
TRPC2, TRPC3, TRPC4 and TRPC6 were ex- 
pressed in the mouse renal cortex, TRPC5 and 
TRPC7 were not detectable. 
To assess the potential role of the DAG-res- 
ponsive TRPC3 and TRPC6 in DN, the expres-
sion of TRPC3/6 in the renal cortex of the WT 
diabetic and nondiabetic mice were examined 
by western blot. TRPC6 protein expression of 
kidney cortical lysates was significantly upre- 
gulated in diabetic WT mice compared with 
nondiabetic WT mice (Figure 1C). The protein 
Figure 2. TRPC3/6/7 deletion reduces the extent of diabetes-induced glomerular enlargement. A, B. RT-PCR showed 
that TRPC3, TRPC6, and TRPC7 were undetectable in the TRPC3/6/7-/- mouse brain, and western blot analysis 
showed that TRPC3 and TRPC6 were indeed deficient in the TRPC3/6/7-/- mouse renal cortex. C, D. Changes in 
blood glucose and body weight. WT-STZ and TRPC3/6/7-/--STZ mice developed similar degrees of hyperglycemia. 
The extent of body weight increase among both diabetic groups was less compared with corresponding nondiabetic 
mice. n=5-11 mice/group. E. PAS staining and its quantitative analysis of glomerular volume in kidney sections, 
magnification ×400. The result showed that glomerular enlargement occurred in both STZ groups (***p<0.001 
and *p<0.05), while the severity of glomerular enlargement in WT-STZ group was greater (**p<0.01). n=5 mice/
group. 
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expression of TRPC3 in the two groups was 
not significantly different (Figure 1C). Western 
blot analysis also demonstrated the increased 
expression of TRPC6 protein in human podo-
cytes treated with HG for 6 days compared to 
NG; no change in TRPC3 protein expression 
was observed between HG-treated and NG- 
treated podocytes (Figure 1D). To exclude os- 
motic effects, the administration of NG+M did 
not significantly affect the protein levels of 
TRPC3 and TRPC6 (Figure 1D).
TRPC3/6/7 deletion reduces the extent of 
diabetes-induced polyuria, kidney hypertrophy 
and glomerular enlargement 
RT-PCR analysis of the TRPC3/6/7-/- mouse 
brain showed that TRPC3, TRPC6 and TRPC7 
mRNA are not detectable in tissues from TR- 
PC3/6/7-/- mice (Figure 2A). Moreover, TRPC3 
and TRPC6 proteins were undetectable in the 
renal cortex of TRPC3/6/7-/- mice by western 
blot (Figure 2B), indicating that the renal cortex 
of TRPC3/6/7-/- mice are indeed deficient in 
TRPC3 and TRPC6. 
After 2 weeks of STZ administration, WT-STZ 
and TRPC3/6/7-/--STZ mice became stably dia-
betic with comparable rises in blood glucose 
levels (Figure 2C, Table 2). The four groups of 
experimental mice exhibited an increase in bo- 
dy weight during the whole experiment, except 
for the body weight of mice in the TRPC3/6/7-/--
STZ group, which slightly decreased during the 
first 4 weeks after STZ injection. However, the 
extent of body weight increase of the two dia-
betic groups was less compared with the non-
diabetic groups (Figure 2D). In addition, the 
body weights of mice in the TRPC3/6/7-/--Veh 
and TRPC3/6/7-/--STZ groups were lower com-
pared with the WT-Veh and WT-STZ groups, 
respectively (Table 2). 
Urine volumes were increased in both diabetic 
groups, but polyuria was alleviated in TRPC3/ 
6/7-/--STZ mice compared with WT-STZ mice 
(Table 2). Kidney hypertrophy occurred in both 
diabetic groups as characterized by increased 
kidney/body weight ratios, though the extent of 
kidney hypertrophy was significantly attenuat-
ed in diabetic TRPC3/6/7-/- mice compared with 
diabetic WT mice (Table 2). Glomerular enlarge-
ment was assessed by glomerular volume in 
PAS-stained kidney sections of mice in four 
groups (Figure 2E). Mice in the diabetic gro- 
ups presented glomerular enlargement, which 
was attenuated in TRPC3/6/7-/- mice (glomeru-
lar volume: WT-STZ versus TRPC3/6/7-/--STZ: 
197651±7643 μm3 versus 153922±6539 
μm3, p<0.01, n=5 mice/group) (Figure 2E).  
TRPC3/6/7 deletion attenuates albumin ex-
cretion and podocyte loss induced by hypergly-
cemia
24 h urine was collected, and albumin levels 
were measured by SDS-polyacrylamide electro-
phoresis followed by Coomassie blue staining. 
As shown in Figure 3A, both STZ groups devel-
oped albuminuria; however, the diabetic TRP- 
C3/6/7-/- mice showed significantly less albu-
minuria than the diabetic WT mice (24 h uri- 
nary albumin: WT versus TRPC3/6/7-/-: 278.40± 
53.84 μg versus 117.6±13.51 μg, p<0.05). 
Podocyte loss was assessed by the amount of 
WT-1 protein in the renal cortex. As shown in 
Figure 3B, the WT-1 protein levels of WT dia-
betic mice was reduced significantly. This alter-
ation was not obviously observed in TRPC3/6/7-
/- diabetic mice, though the WT-1 protein levels 
of TRPC3/6/7-/- diabetic mice showed a declin-
ing trend, indicating that podocyte loss was sig-
nificantly attenuated in TRPC3/6/7-/- diabetic 
mice compared with WT diabetic mice.
Table 2. Characteristics of WT and TRPC3/6/7-/- mice 12 weeks after vehicle or STZ injection
Variable
WT TRPC3/6/7-/-
Veh STZ Veh STZ
n 5 9 5 11
Blood glucose (mmol/l) 6.46±0.27 28.06±2.13aa 6.74±0.39 26.86±1.84bbb
Body weight (g) 27.37±1.73 23.40±0.62a 22.95±0.55a 18.62±0.87bb,cc
Urine volume (ml/24 h) 0.58±0.26 28.93±9.44aa 0.41±0.13 12.97±3.87bbb,c
Kidney/body weight ratio (%) 1.50±0.04 2.42±0.09aa 1.37±0.05 1.68±0.01b,c
Results are shown as means ± SEM. ap<0.05, aap<0.001 vs. WT-Veh; bp<0.05, bbp<0.01, bbbp<0.001 vs. TRPC3/6/7-/--Veh. 
cp<0.01, ccp<0.001, vs. WT-STZ.
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The expression levels of Bcl2, an anti-apoptotic 
protein, and cleaved caspase 3, a pro-apoptot-
ic protein, of kidney cortical lysates were ana-
lyzed by western blot. The expression of Bcl2 
Figure 3. TRPC3/6/7 deletion attenuates albumin excretion and the changes of WT-1, Bcl2, and Cleaved caspase 
3 induced by hyperglycemia. A. 24 h albumin excretion was assessed using SDS electrophoresis and staining of 
gels with Coomassie blue. Both STZ groups developed albuminuria (**p<0.01 and *p<0.05), but albuminuria of 
TRPC3/6/7-/--STZ mice was significantly less than that of WT-STZ mice (*p<0.05). BSA: bovine serum albumin. 
n=5-11 mice/group. B. Western blot showed that WT-1 protein of the renal cortex was decreased obviously in WT-
STZ mice, compared with WT-Veh mice (**p<0.01); however, the decrease were prevented in TRPC3/6/7-/- mice 
(*p<0.05). n=3-5 mice/group. C. Western blot analysis demonstrated that the downregulation of Bcl2 and upregu-
lation of Cleaved caspase 3 in WT-STZ mice (***p<0.001 and **p<0.01) was prevented in TRPC3/6/7-/--STZ mice 
(***p<0.001 and *p<0.05). n=3-5 mice/group. 
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was downregulated, and the amount of cleaved 
caspase 3 was upregulated in the WT diabetic 
renal cortex, although these alterations were 
not significant in TRPC3/6/7-/- mice (Figure 3C).
TRPC3/6/7 deletion inhibits activation of 
TGFβ1 signaling and fibronectin deposition in 
diabetic kidney
Most subtypes of glomerular diseases, includ-
ing DN, are associated with increased TGFβ1 
signaling activity [22]. To determine whether 
the protective effect of the TRPC3/6/7 deletion 
on renal dysfunction and podocyte loss involves 
decreased activation of TGFβ1 signaling, the 
expression of TGFβ1-related proteins was stud-
ied by western blot and immunohistochemistry. 
Western blot analysis showed that the levels of 
TGFβ1 and p-Smad2/3 in the renal cortex in 
diabetic WT mice were significantly increased 
(Figure 4A). Moreover, immunohistochemistry 
showed that TGFβ1 and fibronectin in renal 
glomeruli and tubules were clearly increased in 
WT diabetic mice (Figure 4B). These effects, 
however, were not found in TRPC3/6/7-/- dia-
betic mice (Figure 4). 
Discussion
This study provides evidence for the first time 
that deletion of the DAG-responsive class of 
TRPC genes TRPC3/6/7 in mice attenuates 
DN. Although WT and TRPC3/6/7-/- mice devel-
oped similar degrees of hyperglycemia during 
the study, the TRPC3/6/7-/- mice exhibited lo- 
wer body weights, less polyuria, lower kidney/
body weight ratios, less glomerular enlarge-
ment, less albuminuria, and lowered loss of 
podocytes in the diabetic kidney. To determine 
the underlying mechanism, we found that the 
TRPC3/6/7 deletion blunted the alteration of 
pro-apoptotic mediators in the renal cortex, 
and inhibited activation of TGFβ1 signaling in 
the diabetic kidney. 
Because previous studies had shown that a 
gain-of-function mutation in TRPC6 is associ-
ated with the onset of focal segmental glomer-
ulosclerosis (FSGS) [4, 5], efforts of numerous 
research groups have been focused on the role 
of TRPC6 in proteinuric kidney disease. Re- 
cently, the role of TRPC6 in DN has attracted 
the considerable attention. However, there are 
Figure 4. TRPC3/6/7 deletion inhibits the activation of TGFβ1 signaling and fibronectin deposition in diabetic kid-
ney. A. Western blot analysis showed that TGFβ1 and p-Smad2/3 of renal cortex of WT-STZ mice were increased 
compared with WT-Veh mice (**p<0.01 and *p<0.05); however, the increase was inhibited in TRPC3/6/7-/--STZ 
mice (both *p<0.05). n=3-5 mice/group. B. Immunohistochemistry showed that the deposition of TGFβ1 and Fibro-
nectin in renal cortex of WT-STZ mice were not obvious in TRPC3/6/7-/--mice. n=3-5 mice/group.
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controversies regarding the role of TRPC6 in 
DN. At the beginning of our experiment, we 
observed that the total TRPC6 protein in the 
renal cortex from STZ-induced diabetic mice is 
increased compared with that of nondiabetic 
mice. Moreover, we observed that HG-treated 
cultured human podocytes for 6 days cause 
upregulation of TRPC6 protein. Interestingly, 
Graham et al. demonstrated that TRPC6 pro-
tein in glomeruli isolated from STZ-induced dia-
betic rats was decreased compared with con-
trol rats [23]. The discrepancy with the findings 
reported here might be attributed to the differ-
ent stage of DN, since Graham et al examined 
the expression of TRPC6 protein in glomeruli 2 
weeks after STZ injection. A recent study in 
TRPC3 knockout mice proposed that TRPC3 
channels might constitute important therapeu-
tic targets for improving renal remodeling in kid-
ney disease [10]. However, we did not observe 
significant increases in TRPC3 protein in either 
the renal cortex of STZ-induced diabetic mice or 
in HG-treated podocytes. The cause is not 
clear, and it may be that the model used in their 
research [10] is different than ours or that the 
DN model in our study has not developed to the 
degree of renal fibrosis. These data suggest 
that increased DAG-responsive TRPCs may 
aggravate diabetes-induced renal injury.
Among the TRPC channels, TRPC3, 6 and 7 are 
approximately 75% identical in their amino acid 
sequence. These proteins are believed to asso-
ciate as heterotetramers and form functional 
ion channels on the cell surface [24]. We and 
others have performed various experiments 
in the combined TRPC3/6/7 knockout mouse 
model [25-27], and it has been shown that 
there is an interdependent functional profile of 
TRPC channels in smooth muscle cells of 
TRPC6-deficient mice [16]. Since our data and 
other findings support the role of TRPC3 and 
TRPC6 in kidney disease, in order to more fully 
characterize the impact of deleting closely 
related DAG-responsive TRPC genes (TRPC3/ 
6/7) on the diabetic kidney, we used the avail-
able TRPC3/6/7 triple gene knockout mouse 
strain for our study. We found that the body 
weight of TRPC3/6/7-/- mice was lower than 
that of age-matched WT mice. TRP channels 
are present in most mammalian tissues, and 
can influence diverse physiological processes, 
including adipocyte function, energy intake and 
energy expenditure [28], which may be the 
cause of the small body size. However, the 
mechanism of how TRPC channels influence 
body weight is unclear. It was reported that 
dwarf mice are protected from DN [29]. The 
body weight may thus be related to the develop-
ment of DN. With the exception of the effect of 
TRPC3/6/7 deletion on body weight, no effect 
on normal glomerular structure or function was 
observed in TRPC3/6/7 knockout mice.
The early stage of diabetic mellitus is charac-
terized by renal hyperfiltration, kidney hypertro-
phy, and glomerular enlargement, which pro-
motes the eventual development of DN. Both 
WT and TRPC3/6/7-/- diabetic mice developed 
polyuria and an increase in kidney/body weight 
ratio and glomerular volume. These features 
were attenuated in TRPC3/6/7-/- diabetic mice, 
suggesting that the TRPC3/6/7 deletion plays a 
protective role against renal disorder in STZ-
induced diabetic mice. In contrast, Luan et al. 
[30] reported that tempol improves renal hy- 
perfiltration in STZ-induced diabetic rats via 
increased expression of TRPC6 protein. The 
reasons for these conflicting results are not 
known. 
Recent biopsy studies in humans have provid-
ed evidence that podocytes are functionally 
and structurally injured very early in the natural 
history of DN [31]. Podocyte injury or loss will 
lead to proteinuria and is associated with glo-
merulosclerosis [32]. Here, we found that podo-
cyte loss was significantly attenuated in 
TRPC3/6/7-/- diabetic mice compared with WT 
diabetic mice and that there was a lower albu-
minuria. Similarly, the downregulation of the 
anti-apoptotic protein, Bcl2 and upregulation 
of pro-apoptotic protein, cleaved caspase 3 
observed in WT diabetic mice were not obvious 
in TRPC3/6/7-/- diabetic mice, which is consis-
tent with the finding of podocyte loss. Moreover, 
in vitro studies have shown attenuation of HG- 
induced podocyte apoptosis by TRPC6 gene 
knockdown [8]. These results suggest that 
the TRPC3/6/7 deletion attenuates diabetes-
induced podocyte loss and albuminuria. 
TGFβ1 is a key mediator in chronic kidney dis-
ease associated with progressive renal fibrosis 
[33]. The renal expression of TGFβ1 mRNA as 
well TGFβ1 protein is increased in patients with 
diabetes mellitus [34]. Considerable evidence 
showed that TGFβ1 increases urinary excretion 
of water, electrolytes and glucose by suppress-
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ing tubular reabsorption in both normal and 
diabetic conditions [35-37]. In addition, a num-
ber of previous studies have demonstrated that 
TGFβ1 promotes the development of diabetic 
albuminuria. Transgenic animal models overex-
pressing TGFβ1 exhibit increased urinary excre-
tion of albumin [35]. Furthermore, it was report-
ed that TGFβ1 induces podocyte apoptosis via 
activation of execution caspase 3 [14, 38]. To 
determine whether reducing the upregulation 
of TGFβ1 signaling in TRPC3/6/7-/- diabetic 
mice contributes to the renal protective effect 
of TRPC3/6/7 deletion, we evaluated TGFβ1 
signaling-related proteins in kidneys of diabetic 
WT and KO mice. Results showed that upregu-
lation of TGFβ1, p-Smad2/3 and fibronectin in 
the renal cortex of WT diabetic mice were not 
found in TRPC3/6/7-/- diabetic mice, which may 
be the molecular basis for the presence of 
decreased renal dysfunction and podocyte loss 
in TRPC3/6/7-/- diabetic mice.
In conclusion, the results obtained here provide 
in vivo evidence that knockout of DAG-res- 
ponsive class of TRPC genes TRPC3/6/7 result-
ed in decreased susceptibility to the develop-
ment of renal dysfunction and podocyte loss in 
DN in mice. Additionally, this effect is closely 
associated with inhibiting the activation of the 
TGFβ1 signaling pathway, but the individual 
contributions of TRPC3, TRPC6 and TRPC7 to 
this phenotype are not known. Our data sug-
gest that global inhibition of DAG-responsive 
TRPCs may have a therapeutic benefit in the 
prevention and treatment of DN.
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